Last year alone, Eliquis, marketed by Bristol-Myers Squibb ... At least a half-dozen experimental blood thinners are in development that inhibit a protein called factor XI, one of several blood ...

(Reuters) -Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established drugs like blood thinner Eliquis and cancer treatment Revlimid ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...